(MENAFN) Pfizer, the U.S.-based pharmaceutical giant, revealed its second-quarter financial results on Tuesday, showcasing a robust 10 percent operational growth compared to the same period last year.

The New York-headquartered company reported revenues totaling $14.7 billion, translating to earnings of $0.51 per share.

Updating its full-year outlook, Pfizer now anticipates adjusted earnings per share for 2025 to fall between $2.90 and $3.10, up from the prior guidance of $2.80 to $3.00.

The company reaffirmed its annual revenue forecast, projecting between $61 billion and $64 billion, signaling strong confidence in its core business momentum.

"Our business is performing well and I'm pleased with the progress we achieved in the second quarter," Pfizer Chairman and CEO Albert Bourla said in a statement.

This strong financial performance unfolds amid increasing scrutiny from the White House. Recently, U.S. President Donald Trump issued letters to 17 pharmaceutical firms, including Pfizer, urging significant price cuts on all existing medications for Medicaid recipients, aligning U.S. prices with those seen in Europe.

During Tuesday’s earnings call, Bourla confirmed receipt of the administration’s letter but refrained from detailing how the policy might affect Pfizer. He noted, however, that discussions with the government have been "extremely productive."

Pfizer’s Q2 growth was fueled by notable sales increases across key product lines, including its Vyndaqel cardiomyopathy treatment and COVID-19-related therapies.

MENAFN06082025000045017169ID1109891660